Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial
…, C Queralt, I de Aguirre, B Melloni… - JAMA …, 2015 - jamanetwork.com
Importance The EURTAC trial demonstrated the greater efficacy of erlotinib compared with
chemotherapy for the first-line treatment of European patients with advanced non–small-cell …
chemotherapy for the first-line treatment of European patients with advanced non–small-cell …
Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial
…, F Costes, B Wuyam, T Similowski, B Melloni… - Thorax, 2011 - thorax.bmj.com
… Boris Melloni23, … Court-Fortune, F Costes, B Januel, M Charles); (4) Limoges, France: CHU
du Cluzeau-Dupuytren (B Melloni, MT Antonini, JC Desport, JM Ribardière, F Dalmay), ALAIR…
du Cluzeau-Dupuytren (B Melloni, MT Antonini, JC Desport, JM Ribardière, F Dalmay), ALAIR…
Sortilin mediates the release and transfer of exosomes in concert with two tyrosine kinase receptors
The transfer of exosomes containing both genetic and protein materials is necessary for the
control of the cancer cell microenvironment to promote tumor angiogenesis. The nature and …
control of the cancer cell microenvironment to promote tumor angiogenesis. The nature and …
Treatable traits in the NOVELTY study
…, P Mabire, G Mahay, S Martinez, B Melloni… - …, 2022 - Wiley Online Library
Background and objective Asthma and chronic obstructive pulmonary disease (COPD) are
two prevalent and complex diseases that require personalized management. Although a …
two prevalent and complex diseases that require personalized management. Although a …
[HTML][HTML] Sortilin limits EGFR signaling by promoting its internalization in lung cancer
…, A Magnaudeix, K Durand, F Bertin, B Melloni… - Nature …, 2017 - nature.com
Tyrosine kinase receptors such as the epidermal growth factor receptor (EGFR) transduce
information from the microenvironment into the cell and activate homeostatic signaling …
information from the microenvironment into the cell and activate homeostatic signaling …
[HTML][HTML] Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study
…, P Mabire, G Mahay, S Martinez, B Melloni… - Respiratory …, 2022 - Elsevier
Introduction Persistent cough with sputum production is an important clinical trait in chronic
obstructive pulmonary disease (COPD). We defined “frequent productive cough” based on 2 …
obstructive pulmonary disease (COPD). We defined “frequent productive cough” based on 2 …
[HTML][HTML] Severe asthma standard-of-care background medication reduction with benralizumab: ANDHI in practice substudy
…, Y Douadi, G Mahay, G Devouassoux, B Melloni… - The Journal of Allergy …, 2023 - Elsevier
Background The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind
(DB) study extended understanding of the efficacy of benralizumab for patients with …
(DB) study extended understanding of the efficacy of benralizumab for patients with …
[HTML][HTML] Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria
…, A El Badaoui, A Hitzel, JB Woillard, B Melloni… - Cancer …, 2013 - ncbi.nlm.nih.gov
Introduction: Small cell lung cancer (SCLC) is an aggressive form of lung cancer with poor
prognosis. Adequate staging and therapeutic evaluation is necessary for therapy planning. …
prognosis. Adequate staging and therapeutic evaluation is necessary for therapy planning. …
[HTML][HTML] Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small …
…, N Delacourt, J Ballouhey, T Egenod, B Melloni… - PloS one, 2019 - journals.plos.org
Introduction Although second-line immunotherapy obtained better outcomes than chemotherapy
for patients with advanced non-small–cell lung cancers (NSCLCs), it is expensive and …
for patients with advanced non-small–cell lung cancers (NSCLCs), it is expensive and …
[HTML][HTML] The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study
…, G Mahay, Y Ide, S Martinez, M Inomata, B Melloni… - Respiratory …, 2022 - Elsevier
Background Patients with mild asthma represent a substantial proportion of the population
with asthma, yet there are limited data on their true burden of disease. We aimed to describe …
with asthma, yet there are limited data on their true burden of disease. We aimed to describe …